MX2017013875A - Ciertos inhibidores de la proteína quinasa. - Google Patents

Ciertos inhibidores de la proteína quinasa.

Info

Publication number
MX2017013875A
MX2017013875A MX2017013875A MX2017013875A MX2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A MX 2017013875 A MX2017013875 A MX 2017013875A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitor
certain protein
certain
inhibitors
Prior art date
Application number
MX2017013875A
Other languages
English (en)
Inventor
Weibo Wang
Yang Lijun
Li Tongshuang
Zhao Xingdong
Tan Haohan
Wang Xianlong
Liu Qihong
Jiang Lihua
Liu Yanxin
Lin Min
Sun Jing
Chen Zhifang
LINGHU Li
Chen Ling
Rong Yue
Tan Rui
Zhou Zuwen
Liu Bin
Original Assignee
Chongqing Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198165&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chongqing Fochon Pharmaceutical Co Ltd filed Critical Chongqing Fochon Pharmaceutical Co Ltd
Publication of MX2017013875A publication Critical patent/MX2017013875A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se proporcionan aquí ciertos inhibidores de la CDK4/6, composiciones farmacéuticas de los mismos, y métodos para usarlos.
MX2017013875A 2015-04-28 2016-04-28 Ciertos inhibidores de la proteína quinasa. MX2017013875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154082P 2015-04-28 2015-04-28
PCT/CN2016/080475 WO2016173505A1 (en) 2015-04-28 2016-04-28 Certain protein kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2017013875A true MX2017013875A (es) 2018-06-22

Family

ID=57198165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013875A MX2017013875A (es) 2015-04-28 2016-04-28 Ciertos inhibidores de la proteína quinasa.

Country Status (10)

Country Link
US (1) US10450316B2 (es)
EP (1) EP3288931B2 (es)
CN (1) CN107849012B (es)
BR (1) BR112017023225A2 (es)
DK (1) DK3288931T4 (es)
ES (1) ES2766498T5 (es)
MX (1) MX2017013875A (es)
RU (1) RU2732952C2 (es)
TW (1) TWI696617B (es)
WO (1) WO2016173505A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106559991B (zh) 2014-06-19 2019-09-20 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
CN106608879A (zh) * 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CA3047876C (en) 2016-12-22 2023-08-29 Betta Pharmaceuticals Co., Ltd Benzimidazole derivatives, preparation methods and uses thereof
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
EP3666774B1 (en) 2017-08-11 2022-05-11 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor
CN111315379A (zh) * 2017-08-15 2020-06-19 北京轩义医药科技有限公司 Cdk4/6抑制剂及其用途
EA202190036A1 (ru) * 2018-06-21 2021-03-24 Бетта Фармасьютикалз Ко., Лтд Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение
CN117222411A (zh) * 2021-03-24 2023-12-12 贝达药业股份有限公司 药物组合、包含其的试剂盒及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111716A (ko) * 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
AU2006304875B2 (en) 2005-10-21 2013-01-17 Exelixis, Inc. Pyrazolo-pyrimidines as casein kinase II (CK2) modulators
MX2008013430A (es) 2006-04-19 2009-01-26 Novartis Vaccines & Diagnostic Compuestos de indazol y metodos para la inhibición de cdc7.
EP2331547B1 (en) * 2008-08-22 2014-07-30 Novartis AG Pyrrolopyrimidine compounds as cdk inhibitors
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
RU2515976C2 (ru) * 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
CN105189481A (zh) 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2014375500B2 (en) * 2013-12-31 2017-03-16 Xuanzhu Biopharmaceutical Co., Ltd. Kinase inhibitor and use thereof
CN104910137B (zh) 2014-03-10 2017-04-19 山东轩竹医药科技有限公司 Cdk激酶抑制剂
AU2015292425B2 (en) 2014-07-24 2018-12-20 Beta Pharma, Inc. 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
TW201710257A (zh) 2015-04-17 2017-03-16 艾伯維有限公司 Ｔｎｆ信號傳遞之三環調節劑
CN105153119B (zh) 2015-09-11 2019-01-01 广州必贝特医药技术有限公司 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
RU2680777C1 (ru) * 2018-02-14 2019-02-26 Сергей Викторович Яблочко Направляющий аппарат центробежного многоступенчатого насоса

Also Published As

Publication number Publication date
DK3288931T3 (da) 2020-02-03
EP3288931A4 (en) 2018-10-10
TWI696617B (zh) 2020-06-21
DK3288931T4 (da) 2022-10-24
EP3288931A1 (en) 2018-03-07
CN107849012B (zh) 2021-05-25
ES2766498T3 (es) 2020-06-12
EP3288931B2 (en) 2022-07-20
US20180291027A1 (en) 2018-10-11
RU2017141077A (ru) 2019-05-28
TW201713645A (zh) 2017-04-16
WO2016173505A1 (en) 2016-11-03
EP3288931B1 (en) 2019-11-06
RU2017141077A3 (es) 2019-08-14
RU2732952C2 (ru) 2020-09-24
CN107849012A (zh) 2018-03-27
ES2766498T5 (es) 2022-11-18
US10450316B2 (en) 2019-10-22
BR112017023225A2 (pt) 2018-08-07

Similar Documents

Publication Publication Date Title
PH12020550622A1 (en) Kras g12c inhibitors
MX2022004304A (es) Agentes inductores de apoptosis.
MX2018013983A (es) Inhibidores g12c de kras.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
PH12018500907A1 (en) Inhibitors of ret
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
EP3293177A4 (en) Tyrosine kinase inhibitor and pharmaceutical composition comprising same
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
EP3359159A4 (en) PHARMACEUTICAL SALTS, PHYSICAL FORMS, AND COMPOSITIONS OF PYRROLOPYRIMIDINE INHIBITORS OF KINASES, AND METHODS OF PREPARATION THEREOF
EP3347462A4 (en) METHOD, COMPOSITIONS AND USE OF NOVEL FYN KINASEINHIBITORS
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
PH12018500504A1 (en) Compounds useful for inhibiting ror-gamma-t
IL264593A (en) Medicinal preparations containing akt protein kinase inhibitors
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.